The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Open accessAbstract
Fibroblast growth factor (FGF)2, FGF4, FGF7 and FGF20 are representative paracrine FGFs binding to heparan-sulfate proteoglycan and fibroblast growth factor receptors (FGFRs), whereas FGF19, FGF21 and FGF23 are endocrine FGFs binding to Klotho and FGFRs. FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer. BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FGFR kinases, whereas FGFR1-TACC1, FGFR2-AFF3, FGFR2-BICC1, FGFR2-PPHLN1, FGFR3-BAIAP2L1 and FGFR3-TACC3 fusions in solid tumors are transmembrane-type FGFRs with C-terminal alterations. AZD4547, BGJ398 (infigratinib), Debio-1347 and dovitinib are FGFR1/2/3 inhibitors; BLU9931 is a selective FGFR4 inhibitor; FIIN-2, JNJ-42756493, LY2874455 and ponatinib are pan-FGFR inhibitors. AZD4547, dovitinib and ponatinib are multi-kinase inhibitors targeting FGFRs, colony stimulating factor 1 receptor (CSF1R), vascular endothelial growth factor (VEGF)R2, and others. The tumor microenvironment consists of cancer cells and stromal/immune cells, such as cancer-associated fibroblasts (CAFs), endothelial cells, M2-type tumor-associating macrophages (M2-TAMs), myeloid-derived suppressor cells (MDSCs) and regulatory T cells. FGFR inhibitors elicit antitumor effects directly on cancer cells, as well as indirectly through the blockade of paracrine signaling. The dual inhibition of FGF and CSF1 or VEGF signaling is expected to enhance the antitumor effects through the targeting of immune evasion and angiogenesis in the tumor microenvironment. Combination therapy using tyrosine kinase inhibitors (FGFR or CSF1R inhibitors) and immune checkpoint blockers (anti-PD-1 or anti-CTLA-4 monoclonal antibodies) may be a promising choice for cancer patients. The inhibition of FGF19-FGFR4 signaling is associated with a risk of liver toxicity, whereas the activation of FGF23-FGFR4 signaling is associated with a risk of heart toxicity. Endocrine FGF signaling affects the pathophysiology of cancer patients who are prescribed FGFR inhibitors. Whole-genome sequencing is necessary for the detection of promoter/enhancer alterations of FGFR genes and rare alterations of other genes causing FGFR overexpression. To sustain the health care system in an aging society, a benefit-cost analysis should be performed with a focus on disease-free survival and the total medical cost before implementing genome-based precision medicine for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
Cytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 905
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
Hume, D. A., & MacDonald, K. P. A. (2012) · Blood · doi:10.1182/blood-2011-09-379214 · Cited by 763
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Fagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Ferro, A., Peleteiro, B., Malvezzi, M., Bosetti, C., Bertuccio, P., Levi, F., Negri, E., La Vecchia, C., & Lunet, N. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.029 · Cited by 617
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Self-citationThe transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S., West, B., Bollag, G., McBride, W., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 569
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy
Grabner, A., Amaral, A. P., Schramm, K., Singh, S., Sloan, A., Yanucil, C., Li, J., Shehadeh, L. A., Hare, J. M., David, V., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.002 · Cited by 541
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Condamine, T., Ramachandran, I., Youn, J.-I., & Gabrilovich, D. I. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-052304 · Cited by 521
Wells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J., Pfister, D., Sosa, J. A., Skinner, M., Krebs, A., Vasselli, J., & Schlumberger, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6604 · Cited by 519
Beyond stem cells: self-renewal of differentiated macrophages
Sieweke, M. H., & Allen, J. E. (2013) · Science · doi:10.1126/science.1242974 · Cited by 503
Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501
Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.192 · Cited by 486
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0699 · Cited by 446
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424 · cited 2×
“FGF23 is upregulated by serum phosphate, vitamin D and parathyroid hormone in bone to trans-duce endocrine signaling through FGFR1 and α -Klotho in the kidneys and negative feedback signaling through FGFR3 and α -Klotho in the parathyroid gland (118).”
Marsilje, T. H., Pei, W., Chen, B., Lu, W., Uno, T., Jin, Y., Jiang, T., Kim, S., Li, N., Warmuth, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400402q · Cited by 418
The chemokine system and cancer
Balkwill, F. R. (2012) · The Journal of Pathology · doi:10.1002/path.3029 · Cited by 412
André, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
Tabernero, J., Bahleda, R., Dienstmann, R., Infante, J. R., Mita, A., Italiano, A., Calvo, E., Moreno, V., Adamo, B., Gazzah, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7341 · Cited by 388
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 347
Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 313
Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 311
Colony stimulating factors and myeloid cell biology in health and disease
Hamilton, J. A., & Achuthan, A. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.08.006 · Cited by 285
Ware, K. E., Hinz, T. K., Kleczko, E., Singleton, K. R., Marek, L. A., Helfrich, B. A., Cummings, C. T., Graham, D. K., Astling, D., Tan, A.-C., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.4 · Cited by 249
8p11 myeloproliferative syndrome: a review
Jackson, C. C., Medeiros, L. J., & Miranda, R. N. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.11.003 · Cited by 247
Xie, L., Su, X., Zhang, L., Yin, X., Tang, L., Zhang, X., Xu, Y., Gao, Z., Liu, K., Zhou, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3898 · Cited by 237
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 229
Hovelson, D. H., McDaniel, A. S., Cani, A. K., Johnson, B., Rhodes, K., Williams, P. D., Bandla, S., Bien, G., Choppa, P., Hyland, F., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.03.004 · Cited by 224
Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation
Procopio, M.-G., Laszlo, C., Al Labban, D., Kim, D. E., Bordignon, P., Jo, S.-H., Goruppi, S., Menietti, E., Ostano, P., Ala, U., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3228 · Cited by 223
Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy
Gacche, R. N., & Meshram, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.002 · Cited by 193
Douxfils, J., Haguet, H., Mullier, F., Chatelain, C., Graux, C., & Dogné, J.-M. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5932 · Cited by 192
Su, X., Zhan, P., Gavine, P. R., Morgan, S., Womack, C., Ni, X., Shen, D., Bang, Y.-J., Im, S.-A., Ho Kim, W., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.802 · Cited by 190
Zhao, G., Li, W.-Y., Chen, D., Henry, J. R., Li, H.-Y., Chen, Z., Zia-Ebrahimi, M., Bloem, L., Zhai, Y., Huss, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0306 · Cited by 189
Silswal, N., Touchberry, C. D., Daniel, D. R., McCarthy, D. L., Zhang, S., Andresen, J., Stubbs, J. R., & Wacker, M. J. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00264.2014 · Cited by 188
Byron, S. A., Gartside, M., Powell, M. A., Wellens, C. L., Gao, F., Mutch, D. G., Goodfellow, P. J., & Pollock, P. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030801 · Cited by 186
Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 174
Lee, S. H., Lopes de Menezes, D., Vora, J., Harris, A., Ye, H., Nordahl, L., Garrett, E., Samara, E., Aukerman, S. L., Gelb, A. B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2129 · Cited by 174
Katoh, M. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1444 · Cited by 159
Self-citationShort-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy
Khoo, B. L., Lee, S. C., Kumar, P., Tan, T. Z., Warkiani, M. E., Ow, S. G. W., Nandi, S., Lim, C. T., & Thiery, J. P. (2015) · Oncotarget · doi:10.18632/oncotarget.3903 · Cited by 158
Intertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158
Wynes, M. W., Hinz, T. K., Gao, D., Martini, M., Marek, L. A., Ware, K. E., Edwards, M. G., Böhm, D., Perner, S., Helfrich, B. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3060 · Cited by 156
Carter, E. P., Fearon, A. E., & Grose, R. P. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.003 · Cited by 151
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E. K., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 150
Ross, J. S., Wang, K., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Otto, G. A., He, J., Palmer, G. A., Yelensky, R., Lipson, D., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.135 · Cited by 149
Chell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 146
Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis
Oladipupo, S. S., Smith, C. E., Santeford, A. C., Park, C., Sène, A., Wiley, L. A., Osei‐Owusu, P., Hsu, J., Zapata, N., Liu, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324235111 · Cited by 145
Moughon, D. L., He, H., Schokrpur, S., Jiang, Z. K., Yaqoob, M., David, J., Lin, C. D., Iruela‐Arispe, M. L., Dorigo, O., & Wu, L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3373 · Cited by 136
Helsten, T. L., Schwaederle, M. C., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9579-8 · Cited by 132
Fibroblast growth factor receptors, developmental corruption and malignant disease
Kelleher, F. C., O’Sullivan, H., Smyth, E., McDermott, R., & Viterbo, A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt254 · Cited by 131
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Gartside, M. G., Chen, H., Ibrahimi, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., Bengston, A., Yudt, L. M., Eliseenkova, A. V., Ma, J., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0021 · Cited by 121
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 121
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
André, F., & Cortés, J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3301-y · Cited by 113
FGFR2 Abnormalities Underlie a Spectrum of Bone, Skin, and Cancer Pathologies
Katoh, M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.97 · Cited by 107
Self-citationFusion genes in solid tumors: an emerging target for cancer diagnosis and treatment
Parker, B. C., & Zhang, W. (2013) · 癌症:英文版 · doi:10.5732/cjc.013.10178 · Cited by 103
Jung, E.-J., Jung, E., Min, S. Y., Kim, M. A., & Kim, W. H. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.002 · Cited by 98
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine
Holbrook, J. D., Parker, J. S., Gallagher, K. T., Halsey, W. S., Hughes, A. M., Weigman, V., Lebowitz, P. F., & Kumar, R. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-119 · Cited by 94
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
Choi, H. J., Armaiz-Peña, G. N., Pradeep, S., Cho, M. S., Coleman, R. L., & Sood, A. K. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9538-9 · Cited by 92
Yagasaki, F., Wakao, D., Yokoyama, Y., Uchida, Y., MUROHASHI, I., Kayano, H., Taniwaki, M., Matsuda, A., & Bessho, M. (2001) · PubMed · Cited by 92
Ronca, R., Giacomini, A., Rusnati, M., & Presta, M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1062475 · Cited by 91
Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
Čihorić, N., Savić, S., Schneider, S. S., Ackermann, I., Bichsel-Naef, M., Schmid, R. A., Lardinois, D., Gugger, M., Bubendorf, L., Zlobec, I., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.229 · Cited by 82
Agelopoulos, K., Richter, G. H. S., Schmidt, E. M., Dirksen, U., von Heyking, K., Moser, B., Klein, H., Kontny, U., Dugas, M., Poos, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2744 · Cited by 82
Villanueva, C., Jacobson-Dickman, E. E., Xu, C., Manouvrier‐Hanu, S., Dwyer, A. A., Sykiotis, G. P., Beenken, A., Liu, Y., Tommiska, J., Hu, Y., et al. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.166 · Cited by 78
Pai, R., French, D. M., Ma, N., Hötzel, K., Plise, E. G., Salphati, L., Setchell, K. D. R., Ware, J. A., Lauriault, V., Schutt, L., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs011 · Cited by 78
Wang, J., Mikse, O. R., Liao, R. G., Li, Y. Y., Tan, L., Janne, P. A., Gray, N. S., Wong, K., & Hammerman, P. S. (2014) · Oncogene · doi:10.1038/onc.2014.161 · Cited by 72
Holdman, X. B., Welte, T., Rajapakshe, K., Pond, A. C., Coarfa, C., Mo, Q., Huang, S., Hilsenbeck, S. G., Edwards, D. P., Zhang, X., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0649-1 · Cited by 70
High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer
Preusser, M., Berghoff, A. S., Berger, W., Ilhan‐Mutlu, A., Dinhof, C., Widhalm, G., Dieckmann, K. U., Wöehrer, A., Hackl, M., von Deimling, A., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.004 · Cited by 69
The ins and outs of fibroblast growth factor receptor signalling
Coleman, S. J., Bruce, C., Chioni, A., Kocher, H. M., & Grose, R. P. (2014) · Clinical Science · doi:10.1042/cs20140100 · Cited by 67
Small molecule inhibition of fibroblast growth factor receptors in cancer
Liang, G., Chen, G., Wei, X., Zhao, Y., & Li, X. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.05.002 · Cited by 66
Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells
Zhou, W., Wang, G., & Guo, S. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.10.003 · Cited by 64
Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity
Porta, C., Giglione, P., Liguigli, W., & Paglino, C. (2015) · Future Oncology · doi:10.2217/fon.14.208 · Cited by 64
Wöhrle, S., Weiss, A., Ito, M., Kauffmann, A., Murakami, M., Jagani, Z., Thuery, A., Bauer-Probst, B., Reimann, F., Stamm, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077652 · Cited by 62
Novel Mutations in Neuroendocrine Carcinoma of the Breast
Ang, D. C., Ballard, M., Beadling, C., Warrick, A., Schilling, A., O’Gara, R., Pukay, M., Neff, T. L., West, R. B., Corless, C. L., et al. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pdm.0b013e3182a40fd1 · Cited by 62
Chang, J., Liu, X., Wang, S., Zhang, Z., Wu, Z., Zhang, X., & Li, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105524 · Cited by 61
Notch Regulation of Tumor Angiogenesis
Bridges, E., Oon, C. E., & Harris, A. L. (2011) · Future Oncology · doi:10.2217/fon.11.20 · Cited by 60
Ge, H., Zhang, J., Gong, Y., Gupte, J., Ye, J., Weiszmann, J., Samayoa, K., Coberly, S. K., Gardner, J., Wang, H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.592022 · Cited by 56
Notch signal integration in the vasculature during remodeling
Rostama, B., Peterson, S. M., Vary, C., & Liaw, L. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.10.003 · Cited by 54
Liu, L., Ye, T., Han, Y., Song, H., Zhang, Y. K., Xia, Y., Wang, N., Xiong, Y., Song, X. J., Zhu, Y. X., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358640 · Cited by 53
Targeting angiogenesis in ovarian cancer
Schmitt, J., & Matei, D. E. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.004 · Cited by 53
Chang, J., Wang, S., Zhang, Z., Liu, X., Wu, Z., Geng, R., Ge, X., Dai, C., Liu, R., Zhang, Q., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2987 · Cited by 51
Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis
Xiao, L., Yang, S., Hao, J., Yuan, X., Luo, W., Jiang, L., Hu, Y., Fu, Z., Zhang, Y., & Zou, C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.012 · Cited by 47
Ren, M., Qin, H., Kitamura, E., & Cowell, J. K. (2013) · Blood · doi:10.1182/blood-2013-03-489823 · Cited by 46
Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells
Kwak, Y., Cho, H., Hur, W., & Sim, T. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0032 · Cited by 41
Activating Somatic FGFR2 Mutations in Breast Cancer
Reintjes, N., Li, Y., Becker, A. A., Rohmann, E., Schmutzler, R. K., & Wollnik, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060264 · Cited by 39
Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target
Liu, W., Xie, D.-M., Zhu, G., Huang, G., Lin, Y.-Q., Wang, L., Shi, K., Hu, B., Braddock, M., Chen, Y., et al. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.997711 · Cited by 38
Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer
Bertolini, F., Marighetti, P., Martín-Padura, I., Mancuso, P., Hu‐Lowe, D. D., Shaked, Y., & d’Onofrio, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.007 · Cited by 38
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Tanizaki, J., Ercan, D., Capelletti, M., Dodge, M. E., Xu, C., Bahcall, M., Tricker, E. M., Butaney, M., Calles, A., Sholl, L. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3771 · Cited by 35
Salazar, L., Kashiwada, T. A., Krejčí, P., Meyer, A. N., Casale, M., Hallowell, M., Wilcox, W. R., Donoghue, D. J., & Thompson, L. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086470 · Cited by 35
Künstlinger, H., Fassunke, J., Schildhaus, H., Brors, B., Heydt, C., Ihle, M. A., Mechtersheimer, G., Wardelmann, E., Büttner, R., & Merkelbach‐Bruse, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4046 · Cited by 30
Zhang, T., Zhang, L., Fan, S., Zhang, M., Fu, H., Liu, Y., Yin, X., Chen, H., Xie, L., Zhang, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134493 · Cited by 30
Fibroblast growth factor receptors: multifactorial-contributors to tumor initiation and progression.
Feng, S., Zhou, L., Nice, E. C., & Huang, C. (2015) · PubMed · doi:10.14670/hh-30.13 · Cited by 29
Koika, V., Varnavas, P., Valavani, H., Sidis, Y., Plummer, L., Dwyer, A. A., Quinton, R., Kanaka‐Gantenbein, C., Pitteloud, N., Sertedaki, A., et al. (2012) · Gene · doi:10.1016/j.gene.2012.12.041 · Cited by 28
The angiopoietin/TIE receptor system: Focusing its role for ischemia-reperfusion injury
Hilbert, T., & Klaschik, S. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.10.013 · Cited by 26
Notch signaling in blood vessels: from morphogenesis to homeostasis
Zhang, P., Yan, X., Chen, Y., Yang, Z., & Han, H. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4716-0 · Cited by 24
Kumar, K. R., Chen, W., Koduru, P. R. K., & Luu, H. S. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpud6w1jlqqmna · Cited by 23
Cited by
Cancer immunotherapy: Pros, cons and beyond
Tan, S., Li, D., & Zhu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 688
Fibroblasts as immune regulators in infection, inflammation and cancer
Davidson, S., Coles, M., Thomas, T., Kollias, G., Ludewig, B., Turley, S., Brenner, M., & Buckley, C. D. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00540-z · Cited by 605
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Self-citationKrook, M. A., Reeser, J. W., Ernst, G., Barker, H., Wilberding, M., Li, G., Chen, H.-Z., & Roychowdhury, S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01157-0 · Cited by 363
Metadata
- Authors
- KATOH, M.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2016-05-31
- Volume
- 38
- Issue
- 1
- Pages
- 3-15
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W2409987903
- Cited by
- 405
- References
- 135
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.